{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:59:18Z","timestamp":1787065158622,"version":"build-2736575974"},"reference-count":128,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,4,1]],"date-time":"2015-04-01T00:00:00Z","timestamp":1427846400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["annalspathology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Diagnostic Pathology"],"published-print":{"date-parts":[[2015,4]]},"DOI":"10.1016\/j.anndiagpath.2015.01.002","type":"journal-article","created":{"date-parts":[[2015,1,15]],"date-time":"2015-01-15T12:47:29Z","timestamp":1421326049000},"page":"91-98","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Angiogenesis in primary hyperparathyroidism"],"prefix":"10.1016","volume":"19","author":[{"given":"Oliwia Anna","family":"Segiet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Michalski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlena","family":"Brzozowa-Zasada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adam","family":"Piecuch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ma\u0142gorzata","family":"\u017baba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Helewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Gabriel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romuald","family":"Wojnicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0380","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0065-230X(08)60946-X","article-title":"Tumor angiogenesis","volume":"43","author":"Folkman","year":"1985","journal-title":"Adv Cancer Res"},{"issue":"6","key":"10.1016\/j.anndiagpath.2015.01.002_bb0385","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/nrc1093","article-title":"Tumorigenesis and the angiogenic switch","volume":"3","author":"Bergers","year":"2003","journal-title":"Nat Rev Cancer"},{"issue":"21","key":"10.1016\/j.anndiagpath.2015.01.002_bb0390","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1056\/NEJM197111182852108","article-title":"Tumor angiogenesis: therapeutic implications","volume":"285","author":"Folkman","year":"1971","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0395","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1146\/annurev.med.57.121304.131306","article-title":"Angiogenesis","volume":"57","author":"Folkman","year":"2006","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0400","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/S0140-6736(09)60507-9","article-title":"Hyperparathyroidism","volume":"374","author":"Fraser","year":"2009","journal-title":"Lancet"},{"issue":"Suppl. 2","key":"10.1016\/j.anndiagpath.2015.01.002_bb0405","first-page":"18","article-title":"Epidemiology of primary hyperparathyroidism in Europe","volume":"17","author":"Adami","year":"2002","journal-title":"J Bone Miner"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0410","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/S0039-6060(96)80060-2","article-title":"Stimulation of angiogenesis by canine parathyroid tissue","volume":"120","author":"Carter","year":"1996","journal-title":"Surgery"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0415","first-page":"1138","article-title":"Angiogenesis of human parathyroid tissue","volume":"96","author":"Saxe","year":"1984","journal-title":"Surgery"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0420","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1067\/msy.2000.107102","article-title":"Parathyroid-induced angiogenesis is VEGF-dependent","volume":"128","author":"Carter","year":"2000","journal-title":"Surgery"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0425","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/S0039-6060(99)70201-1","article-title":"Parathyroid autotransplantation with total thyroidectomy for thyroid carcinoma: long-term follow-up of grafted parathyroid function","volume":"125","author":"Kikumori","year":"1999","journal-title":"Surgery"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0430","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/00007890-199808270-00006","article-title":"Autotransplantation of rat parathyroid glands: a study on morphological changes","volume":"66","author":"Luts","year":"1998","journal-title":"Transplantation"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0435","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1067\/msy.2001.118386","article-title":"Parathyroid-produced angiopoietin-2 modulates angiogenic response","volume":"130","author":"Carter","year":"2001","journal-title":"Surgery"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0440","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1002\/(SICI)1097-0215(19990621)84:3<293::AID-IJC16>3.0.CO;2-T","article-title":"Molecular mediators of tumor angiogenesis: enhanced expression and activation of vascular endothelial growth factor receptor KDR in primary breast cancer","volume":"84","author":"Kranz","year":"1999","journal-title":"Int J Cancer"},{"issue":"2C","key":"10.1016\/j.anndiagpath.2015.01.002_bb0445","first-page":"1537","article-title":"Renal cell carcinoma: relevance of angiogenetic factors","volume":"19","author":"Wechsel","year":"1999","journal-title":"Anticancer Res"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0450","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1002\/(SICI)1097-0215(19990611)81:6<845::AID-IJC1>3.0.CO;2-5","article-title":"Vascular endothelial growth factor is up-regulated in the early pre-malignant stage of colorectal tumour progression","volume":"81","author":"Wong","year":"1999","journal-title":"Int J Cancer"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0455","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1186\/1471-2407-12-298","article-title":"Tumor stromal vascular endothelial growth factor A is predictive of poor outcome in inflammatory breast cancer","volume":"12","author":"Arias-Pulido","year":"2012","journal-title":"BMC Cancer"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0460","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1016\/j.febslet.2006.03.087","article-title":"Biology of vascular endothelial growth factors","volume":"580","author":"Roy","year":"2006","journal-title":"FEBS Lett"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0465","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/nrm1911","article-title":"VEGF receptor signaling-in control of vascular function","volume":"7","author":"Olsson","year":"2006","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"4","key":"10.1016\/j.anndiagpath.2015.01.002_bb0470","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1210\/er.2003-0027","article-title":"Vascular endothelial growth factor: basic science and clinical progress","volume":"25","author":"Ferrara","year":"2004","journal-title":"Endocr Rev"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0475","first-page":"RE21","article-title":"VEGF receptor signal transduction","volume":"112","author":"Matsumoto","year":"2001","journal-title":"Sci STKE"},{"issue":"3","key":"10.1016\/j.anndiagpath.2015.01.002_bb0480","first-page":"245","article-title":"Hypoxia-driven angiogenesis: role of tip cells and extracellular matrix scaffolding","volume":"17","author":"Germain","year":"2010","journal-title":"Curr Opin Hematol"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0485","doi-asserted-by":"crossref","first-page":"51","DOI":"10.3389\/fnmol.2011.00051","article-title":"PI3K\/AKT\/mTOR pathway in angiogenesis","volume":"4","author":"Karar","year":"2011","journal-title":"Front Mol Neurosci"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0490","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1158\/1078-0432.CCR-06-1865","article-title":"The von Hippele Lindau tumor suppressor protein and clear cell renal carcinoma","volume":"13","author":"Kaelin","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0495","first-page":"490","article-title":"Oncogenes and tumor angiogenesis: differential modes of vascular endothelial growth factor up-regulation in ras-transformed epithelial cells and fibroblasts","volume":"60","author":"Rak","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0500","doi-asserted-by":"crossref","first-page":"25915","DOI":"10.1074\/jbc.270.43.25915","article-title":"Both v-Ha-Ras and v-Raf stimulate expression of the vascular endothelial growth factor in NIH 3T3 cells","volume":"270","author":"Grugel","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0505","doi-asserted-by":"crossref","first-page":"18165","DOI":"10.1074\/jbc.273.29.18165","article-title":"p42\/p44 MAP kinase module plays a key role in the transcriptional regulation of vascular endothelial growth factor gene in fibroblasts","volume":"273","author":"Milanini","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0510","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1161\/01.RES.83.3.233","article-title":"Tie2 receptor ligands, angiopoietin-1 and angiopoietin-2, modulate VEGF-induced postnatal neovascularization","volume":"83","author":"Asahara","year":"1998","journal-title":"Circ Res"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0515","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/S0092-8674(00)81812-7","article-title":"Isolation of angiopoietin-1, a ligand for the Tie-2 receptor, by secretion trap expression cloning","volume":"87","author":"Davis","year":"1996","journal-title":"Cell"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0520","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1126\/science.277.5322.55","article-title":"Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis","volume":"277","author":"Maisonpierre","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0525","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1055\/s-2007-979098","article-title":"Apoptosis and growth factors in parathyroid adenomas","volume":"29","author":"Kvasnicka","year":"1997","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0530","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1093\/oxfordjournals.ndt.a027131","article-title":"De novo expression of transforming growth factor-alpha in parathyroid gland tissue of patients with primary or secondary uraemic hyperparathyroidism","volume":"11","author":"Gogusev","year":"1996","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0535","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1007\/s002689900125","article-title":"Effect of growth factors on growth of bovine parathyroid cells in serum-free medium","volume":"20","author":"Sadler","year":"1996","journal-title":"World J Surg"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0540","doi-asserted-by":"crossref","first-page":"6","DOI":"10.3389\/fendo.2013.00006","article-title":"Anabolic effects of IGF-1 signaling on the skeleton","volume":"4","author":"Tahimic","year":"2013","journal-title":"Front Endocrinol"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0545","doi-asserted-by":"crossref","first-page":"23249","DOI":"10.1074\/jbc.274.33.23249","article-title":"Parathyroid hormone-(1-34) enhances aggrecan synthesis via an insulin-like growth factor-I pathway","volume":"274","author":"Harvey","year":"1999","journal-title":"J Biol Chem"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0550","doi-asserted-by":"crossref","first-page":"4349","DOI":"10.1210\/endo.142.10.8436","article-title":"Evidence that anabolic effects of PTH on bone require IGF-I in growing mice","volume":"142","author":"Miyakoshi","year":"2001","journal-title":"Endocrinology"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0555","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1359\/jbmr.070517","article-title":"IGF-I receptor is required for the anabolic actions of parathyroid hormone on bone","volume":"22","author":"Wang","year":"2007","journal-title":"J Bone Miner Res"},{"issue":"Suppl. 1","key":"10.1016\/j.anndiagpath.2015.01.002_bb0560","first-page":"101","article-title":"IGF-I signaling regulates the interaction of osteoblasts and osteoclasts via the RANKL\/RANK and ephrin B2\/EphB4 signaling pathways","volume":"25","author":"Wang","year":"2010","journal-title":"J Bone Miner Res"},{"issue":"4","key":"10.1016\/j.anndiagpath.2015.01.002_bb0565","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/BF00353784","article-title":"Insulin-like growth factor 1 receptors and insulin-like growth factor-binding proteins in human parathyroid tumors","volume":"18","author":"Tanaka","year":"1994","journal-title":"World J Surg"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0570","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1007\/s002689900112","article-title":"Epidermal growth factor receptor status in hyperparathyroidism: immunocytochemical and in situ hybridization study","volume":"20","author":"Sadler","year":"1996","journal-title":"World J Surg"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0575","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1530\/eje.1.02168","article-title":"Immunohistochemical investigation of angiogenic factors in parathyroid proliferative lesions","volume":"154","author":"Lazaris","year":"2006","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0580","first-page":"2898","article-title":"Vascular endothelial growth factor (VEGF) in breast cancer: comparison of plasma, serum, and tissue VEGF and microvessel density and effects of tamoxifen","volume":"60","author":"Adams","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0585","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.1210\/jc.2003-031651","article-title":"Angiogenesis and lymphangiogenesis in parathyroid proliferative lesions","volume":"89","author":"Garcia-Torre","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0590","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/S0960-9822(95)00102-3","article-title":"Functions of fibroblast growth factors and their receptors","volume":"5","author":"Wilkie","year":"1995","journal-title":"Curr Biol"},{"issue":"Suppl. 9","key":"10.1016\/j.anndiagpath.2015.01.002_bb0595","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1161\/01.CIR.92.9.365","article-title":"Synergistic effect of vascular endothelial growth factor and basic fibroblast growth factor on angiogenesis in vivo","volume":"92","author":"Asahara","year":"1995","journal-title":"Circulation"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0600","first-page":"2681","article-title":"Analysis of proliferative activity of the parathyroid glands using proliferating cell nuclear antigen in patients with hyperparathyroidism","volume":"82","author":"Yamaguchi","year":"1997","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0605","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1080\/0031302021000009360","article-title":"Flow cytometric DNA analysis of benign hyperfunctioning parathyroid glands: significant difference in the S phase fraction and proliferative index between adenomas and hyperplasias","volume":"34","author":"Berczi","year":"2002","journal-title":"Pathology"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0610","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1677\/joe.0.1650475","article-title":"Angiogenesis in pituitary adenomas\u2014relationship to endocrine function, treatment and outcome","volume":"165","author":"Turner","year":"2000","journal-title":"J Endocrinol"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0615","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1038\/ki.1995.446","article-title":"Calcium-regulated parathyroid hormone release in patients with mild or advanced secondary hyperparathyroidism","volume":"48","author":"Goodman","year":"1995","journal-title":"Kidney Int"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0620","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/j.1442-2042.1996.tb00497.x","article-title":"In vitro hormone release in patients with secondary hyperparathyroidism","volume":"3","author":"Yano","year":"1996","journal-title":"Int J Urol"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0625","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/S0002-9440(10)64568-3","article-title":"Patterns of chromosomal imbalances in parathyroid carcinomas","volume":"157","author":"Kytola","year":"2000","journal-title":"Am J Pathol"},{"issue":"8","key":"10.1016\/j.anndiagpath.2015.01.002_bb0630","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1002\/ijc.27316","article-title":"Cellular senescence and tumor suppressor gene p16","volume":"130","author":"Rayess","year":"2012","journal-title":"Int J Cancer"},{"issue":"10","key":"10.1016\/j.anndiagpath.2015.01.002_bb0635","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/35096061","article-title":"The INK4a\/ARF network in tumour suppression","volume":"2","author":"Sherr","year":"2001","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0640","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1006\/geno.1994.1536","article-title":"Assignment of the endothelial-specific protein receptor tyrosine kinase gene (TEK) to human chromosome 9p21","volume":"23","author":"Dumont","year":"1994","journal-title":"Genomics"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0645","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1086\/302450","article-title":"A gene for inherited cutaneous venous anomalies (\u201cglomangiomas\u201d) localizes to chromosome 1p21-22","volume":"65","author":"Boon","year":"1999","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0010","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1136\/jmg.34.8.617","article-title":"Localisation of a gene causing endocrine neoplasia to a 4cM region on chromosome 1p35-p36","volume":"34","author":"Williamson","year":"1997","journal-title":"J Med Genet"},{"issue":"31","key":"10.1016\/j.anndiagpath.2015.01.002_bb0015","doi-asserted-by":"crossref","first-page":"3470","DOI":"10.1038\/sj.onc.1203672","article-title":"Expression of the vascular endothelial growth factor gene is inhibited by p73","volume":"19","author":"Salimath","year":"2000","journal-title":"Oncogene"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0020","first-page":"1766","article-title":"Novel chromosomal abnormalities identified by comparative genomic hybridization in parathyroid adenomas","volume":"83","author":"Palanisamy","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0025","doi-asserted-by":"crossref","first-page":"86-84","DOI":"10.1002\/path.1489","article-title":"Differential expression of the calcium sensing receptor and combined loss of chromosome 1p and 11q in parathyroid carcinoma","volume":"202","author":"Haven","year":"2004","journal-title":"J Pathol"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0030","first-page":"578-574","article-title":"Analysis of parathyroid neoplasms by interphase fluorescence in situ hybridization","volume":"38","author":"Erickson","year":"2004","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0035","first-page":"355","article-title":"Identification and cloning of two overexpressed genes, U21B31\/PRAD1 and EMS1, within the amplified chromosome 11q13 region in human carcinomas","volume":"7","author":"Schuuring","year":"1992","journal-title":"Oncogene"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0040","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1002\/path.1481","article-title":"High-throughput tissue microarray analysis of 11q13 gene amplification (CCND1, FGF3, FGF4, EMS1) in urinary bladder cancer","volume":"201","author":"Zaharieva","year":"2003","journal-title":"J Pathol"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0045","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1161\/01.CIR.93.6.1079","article-title":"Novel human vascular endothelial growth factor genes VEGF-B and VEGF-C localize to chromosomes 11q13 and 4q34, respectively","volume":"93","author":"Paavonen","year":"1996","journal-title":"Circulation"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0050","series-title":"Primer on the metabolic bone diseases and disorders of mineral metabolism","first-page":"361","article-title":"Familial hyperparathyroidism (including MEN, FHH, and HPT-JT)","author":"Arnold","year":"2008"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0055","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/S1043-2760(00)00372-6","article-title":"Multiple endocrine neoplasia type 1: new clinical and basic findings","volume":"12","author":"Schussheim","year":"2001","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0060","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1126\/science.276.5311.404","article-title":"Positional cloning of the gene for multiple endocrine neoplasia-type 1","volume":"276","author":"Chandrasekharappa","year":"1997","journal-title":"Science"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0065","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0092-8674(00)80967-8","article-title":"Menin interacts with the AP1 transcription factor JunD and represses JunD activated transcription","volume":"96","author":"Agarwal","year":"1999","journal-title":"Cell"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0070","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1530\/eje.0.1430047","article-title":"Frequency of somatic MEN1 gene mutations in monoclonal parathyroid tumours of patients with primary hyperparathyroidism","volume":"143","author":"Miedlich","year":"2000","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0075","first-page":"5553","article-title":"Screening of the Men1 gene and discovery of germ-line and somatic mutations in apparently sporadic parathyroid tumors","volume":"60","author":"Uchino","year":"2000","journal-title":"Cancer Res"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0080","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1007\/BF03345303","article-title":"Novel somatic MEN1 gene alterations in sporadic primary hyperparathyroidism and correlation with clinical characteristics","volume":"27","author":"Scarpelli","year":"2004","journal-title":"J Endocrinol Invest"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0085","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1007\/BF03346498","article-title":"Mutation analysis of MEN1, HRPT2, CASR, CDKN1B, and AIP genes in primary hyperparathyroidism patients with features of genetic predisposition","volume":"32","author":"Vierimaa","year":"2009","journal-title":"J Endocrinol Invest"},{"issue":"4","key":"10.1016\/j.anndiagpath.2015.01.002_bb0090","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S0002-9440(10)64406-9","article-title":"Independent genetic events associated with the development of multiple parathyroid tumors in patients with primary hyperparathyroidism","volume":"161","author":"Dwight","year":"2002","journal-title":"Am J Pathol"},{"issue":"1","key":"10.1016\/j.anndiagpath.2015.01.002_bb0095","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3109\/10623329709044157","article-title":"HPE cells: a clonal endothelial cell line established from human parathyroid tissue (human parathyroid cell line)","volume":"5","author":"Benvenuti","year":"1997","journal-title":"Endothelium"},{"issue":"11","key":"10.1016\/j.anndiagpath.2015.01.002_bb0100","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1096\/fasebj.7.11.8370472","article-title":"Pericyte physiology","volume":"7","author":"Shepro","year":"1993","journal-title":"FASEB J"},{"issue":"3","key":"10.1016\/j.anndiagpath.2015.01.002_bb0105","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/S0002-9440(10)64920-6","article-title":"Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors","volume":"160","author":"Morikawa","year":"2002","journal-title":"Am J Pathol"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0110","first-page":"372","article-title":"Induction of alpha-smooth muscle actin expression in cultured human brain pericytes by transforming growth factor-beta 1","volume":"144","author":"Verbeek","year":"1994","journal-title":"Am J Pathol"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0115","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF00268014","article-title":"The versatility of microvascular pericytes: from mesenchyme to smooth muscle?","volume":"99","author":"Nehls","year":"1993","journal-title":"Histochemistry"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0120","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/BF00645048","article-title":"Pericyte involvement in capillary sprouting during angiogenesis in situ","volume":"270","author":"Nehls","year":"1992","journal-title":"Cell Tissue Res"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0125","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0021-9150(96)06050-9","article-title":"Cultured retinal pericytes stimulate in vitro angiogenesis of endothelial cells through secretion of a fibroblast growth factor-like molecule","volume":"130","author":"Watanabe","year":"1997","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0130","first-page":"67","article-title":"Angiogenic interaction between retinal endothelial cells and pericytes from normal and diabetic rabbits, and phenotypic changes of diabetic cells","volume":"45","author":"Morisaki","year":"1999","journal-title":"Cell Mol Biol"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0135","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1161\/01.HYP.31.1.511","article-title":"Vascular endothelial growth factor mRNA in pericytes is upregulated by phorbol myristate acetate","volume":"31","author":"Kim","year":"1998","journal-title":"Hypertension"},{"issue":"23","key":"10.1016\/j.anndiagpath.2015.01.002_bb0140","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N Engl J Med"},{"issue":"24","key":"10.1016\/j.anndiagpath.2015.01.002_bb0145","doi-asserted-by":"crossref","first-page":"2542","DOI":"10.1056\/NEJMoa061884","article-title":"Paclitaxel-carboplatin alone or with bevacizumab for non\u2013small-cell lung cancer","volume":"355","author":"Sandler","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0150","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/S0140-6736(07)61904-7","article-title":"Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, doubleblind phase III trial","volume":"370","author":"Escudier","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0155","doi-asserted-by":"crossref","first-page":"4733","DOI":"10.1200\/JCO.2008.19.8721","article-title":"Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma","volume":"27","author":"Friedman","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0160","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1200\/JCO.2008.16.3055","article-title":"Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma","volume":"27","author":"Kreisl","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0165","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1056\/NEJMoa1104390","article-title":"Incorporation of bevacizumab in the primary treatment of ovarian cancer","volume":"365","author":"Burger","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0170","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","article-title":"A phase 3 trial of bevacizumab in ovarian cancer","volume":"365","author":"Perren","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0175","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1126\/science.1104819","article-title":"Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy","volume":"307","author":"Jain","year":"2005","journal-title":"Science"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0180","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","article-title":"BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis","volume":"64","author":"Wilhelm","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0185","first-page":"327","article-title":"In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic\/pharmacodynamic relationship","volume":"9","author":"Mendel","year":"2003","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0190","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1056\/NEJMoa0708857","article-title":"Sorafenib in advanced hepatocellular carcinoma","volume":"359","author":"Llovet","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0195","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa060655","article-title":"Sorafenib in advanced clear-cell renal-cell carcinoma","volume":"356","author":"Escudier","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0200","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1200\/JCO.2009.26.7856","article-title":"Activity of sorafenib in recurrent ovarian cancer and primary peritoneal carcinomatosis: a gynecologic oncology group trial","volume":"29","author":"Matei","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0205","doi-asserted-by":"crossref","first-page":"3330","DOI":"10.1200\/JCO.2009.25.6834","article-title":"Phase II evaluation of sorafenib in advanced and metastatic squamous cell carcinoma of the head and neck: Southwest Oncology Group Study S0420","volume":"28","author":"Williamson","year":"2010","journal-title":"J Clin Oncol"},{"issue":"33","key":"10.1016\/j.anndiagpath.2015.01.002_bb0210","doi-asserted-by":"crossref","first-page":"5352","DOI":"10.1200\/JCO.2007.15.7461","article-title":"Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor","volume":"26","author":"Heinrich","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0215","doi-asserted-by":"crossref","first-page":"4068","DOI":"10.1200\/JCO.2008.20.5476","article-title":"Phase II study of sunitinib administered in a continuous once-daily dosing regimen in patients with cytokine-refractory metastatic renal cell carcinoma","volume":"27","author":"Escudier","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0220","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJMoa1003825","article-title":"Sunitinib malate for the treatment of pancreatic neuroendocrine tumors","volume":"364","author":"Raymond","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0225","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJMoa065044","article-title":"Sunitinib versus interferon alfa in metastatic renal cell carcinoma","volume":"356","author":"Motzer","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0230","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1200\/JCO.2008.20.1293","article-title":"Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma","volume":"27","author":"Motzer","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0235","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1093\/annonc\/mds003","volume":"23","author":"Baumann","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0240","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ygyno.2009.08.012","article-title":"A phase II study of sunitinib in patients with locally advanced or metastatic cervical carcinoma: NCIC CTG Trial IND.184","volume":"116","author":"Mackay","year":"2010","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0245","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1200\/JCO.2009.23.8584","article-title":"Phase II study of sunitinib in recurrent or metastatic squamous cell carcinoma of the head and neck: GORTEC 2006-01","volume":"28","author":"Machiels","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0250","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1056\/NEJMoa066838","article-title":"Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma","volume":"356","author":"Hudes","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0255","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/S0140-6736(08)61039-9","article-title":"Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial","volume":"372","author":"Motzer","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0260","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1186\/1471-2407-10-368","article-title":"Inhibition of the mammalian target of rapamycin (mTOR) in advanced pancreatic cancer: results of two phase II studies","volume":"10","author":"Javle","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0265","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0270","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/S1470-2045(11)70062-6","article-title":"Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study","volume":"12","author":"Ansell","year":"2011","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0275","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/annonc\/mdq320","article-title":"Temsirolimus in VEGF-refractory metastatic renal cell carcinoma","volume":"22","author":"Mackenzie","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0280","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1158\/0008-5472.CAN-09-2340","article-title":"Beyond rapalog therapy: preclinical pharmacology and antitumor activity of WYE-125132, an ATP-competitive and specific inhibitor of mTORC1 and mTORC2","volume":"70","author":"Yu","year":"2010","journal-title":"Cancer Res"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0285","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1002\/1097-0142(197303)31:3<600::AID-CNCR2820310316>3.0.CO;2-0","article-title":"Parathyroid carcinoma. A study of 70 cases","volume":"31","author":"Schantz","year":"1973","journal-title":"Cancer"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0290","series-title":"WHO classification of tumours","first-page":"124","article-title":"Pathology and genetics of the tumours of endocrine organs","author":"DeLellis","year":"2006"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0295","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s12022-008-9050-2","article-title":"Challenging lesions in the differential diagnosis of endocrine tumors: parathyroid carcinoma","volume":"19","author":"DeLellis","year":"2008","journal-title":"Endocr Pathol"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0300","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/ng1048","article-title":"HRPT2, encoding parafibromin, is mutated in hyperparathyroidism-jaw tumor syndrome","volume":"32","author":"Carpten","year":"2002","journal-title":"Nat Genet"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0305","doi-asserted-by":"crossref","first-page":"17420","DOI":"10.1073\/pnas.0710725105","article-title":"The parafibromin tumor suppressor protein inhibits cell proliferation by repression of the c-myc proto-oncogene","volume":"105","author":"Lin","year":"2008","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0310","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1158\/1541-7786.MCR-06-0129","article-title":"Nuclear localization of the parafibromin tumor suppressor protein implicated in the hyperparathyroidism\u2013jaw tumor syndrome enhances its proapoptotic function","volume":"5","author":"Lin","year":"2007","journal-title":"Mol Cancer Res"},{"issue":"2","key":"10.1016\/j.anndiagpath.2015.01.002_bb0315","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/hed.21716","article-title":"Parafibromin immunohistochemical staining to differentiate parathyroid carcinoma from parathyroid adenoma","volume":"34","author":"Kim","year":"2012","journal-title":"Head Neck"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0320","doi-asserted-by":"crossref","first-page":"6629","DOI":"10.1158\/1078-0432.CCR-04-0493","article-title":"Loss of parafibromin immunoreactivity is a distinguishing feature of parathyroid carcinoma","volume":"10","author":"Tan","year":"2004","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0325","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s00428-010-1032-3","article-title":"Absence of nucleolar parafibromin immunoreactivity in subsets of parathyroid malignant tumours","volume":"459","author":"Juhlin","year":"2011","journal-title":"Virchows Arch"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0330","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s12022-010-9121-z","article-title":"Parafibromin and APC as screening markers for malignant potential in atypical parathyroid adenomas","volume":"21","author":"Juhlin","year":"2010","journal-title":"Endocr Pathol"},{"issue":"16","key":"10.1016\/j.anndiagpath.2015.01.002_bb0335","first-page":"2895","article-title":"Expression of Ki-67, galectin-3, fragile histidine triad, and parafibromin in malignant and benign parathyroid tumors","volume":"125","author":"Wang","year":"2012","journal-title":"Chin Med J (Engl)"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0340","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1530\/EJE-06-0720","article-title":"Should parafibromin staining replace HRPT2 gene analysis as an additional tool for histologic diagnosis of parathyroid carcinoma?","volume":"156","author":"Cetani","year":"2007","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0345","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1056\/NEJMoa031237","article-title":"Somatic and germ-line mutations of the HRPT2 gene in sporadic parathyroid carcinoma","volume":"349","author":"Shattuck","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0350","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1136\/jmg.40.9.657","article-title":"HRPT2 mutations are associated with malignancy in sporadic parathyroid tumours","volume":"40","author":"Howell","year":"2003","journal-title":"J Med Genet"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0355","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1097\/01.pas.0000209827.39477.4f","article-title":"Loss of nuclear expression of parafibromin distinguishes parathyroid carcinomas and hyperparathyroidism\u2013jaw tumour (HPT-JT) syndrome-related adenomas from sporadic parathyroid adenomas and hyperplasias","volume":"30","author":"Gill","year":"2006","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"10.1016\/j.anndiagpath.2015.01.002_bb0360","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9","article-title":"The Ki-67 protein: from the known and the unknown","volume":"182","author":"Scholzen","year":"2000","journal-title":"J Cell Physiol"},{"issue":"5","key":"10.1016\/j.anndiagpath.2015.01.002_bb0365","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S1092-9134(99)80024-0","article-title":"Immunohistochemical study of fatty acid synthase, Ki67, proliferating cell nuclear antigen, and p53 expression in hyperplastic parathyroids","volume":"3","author":"Al\u00f2","year":"1999","journal-title":"Ann Diagn Pathol"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0370","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1053\/hupa.2003.55","article-title":"Parathyroid neoplasms: clinical, histopathological, and tissue microarraybased molecular analysis","volume":"34","author":"Stojadinovic","year":"2003","journal-title":"Hum Pathol"},{"key":"10.1016\/j.anndiagpath.2015.01.002_bb0375","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1007\/BF02738728","article-title":"Immunohistochemical analysis of the cell cycle\u2013associated antigens Ki-67 and retinoblastoma protein in parathyroid carcinomas and adenomas","volume":"6","author":"Lloyd","year":"1995","journal-title":"Endocr Pathol"}],"container-title":["Annals of Diagnostic Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1092913415000039?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1092913415000039?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,19]],"date-time":"2019-08-19T15:15:40Z","timestamp":1566227740000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1092913415000039"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,4]]},"references-count":128,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,4]]}},"alternative-id":["S1092913415000039"],"URL":"https:\/\/doi.org\/10.1016\/j.anndiagpath.2015.01.002","relation":{},"ISSN":["1092-9134"],"issn-type":[{"value":"1092-9134","type":"print"}],"subject":[],"published":{"date-parts":[[2015,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Angiogenesis in primary hyperparathyroidism","name":"articletitle","label":"Article Title"},{"value":"Annals of Diagnostic Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anndiagpath.2015.01.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}